Answers are grounded in this paper and cite their sources.
Case demonstrates pembrolizumab-induced primary adrenal insufficiency in a geriatric patient, highlighting critical management needs.
Pembrolizumab, a PD-1 checkpoint inhibitor, is widely used in the treatment of various malignancies. While it improves overall survival, it can lead to immune-related adverse events (irAEs), including rare endocrine disorders such as primary adrenal insufficiency (PAI). We present a case of PAI induced by Pembrolizumab in a 75-year-old man, emphasizing the importance of early recognition and timely management.
No takes yet. Share an insight, caveat, or question.
Raza et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: